Last reviewed · How we verify
Everolimus+Tacrolimus+Prednisone
This triple immunosuppressive regimen inhibits T-cell proliferation and activation to prevent organ rejection after transplantation.
This triple immunosuppressive regimen inhibits T-cell proliferation and activation to prevent organ rejection after transplantation. Used for Prevention of organ rejection in renal transplant recipients.
At a glance
| Generic name | Everolimus+Tacrolimus+Prednisone |
|---|---|
| Also known as | Certican, Tacrolimus, Prednisone |
| Sponsor | Fundação Pró Rim |
| Drug class | Immunosuppressive combination therapy |
| Target | mTOR (everolimus), calcineurin (tacrolimus), glucocorticoid receptor (prednisone) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Transplantation |
| Phase | FDA-approved |
Mechanism of action
Everolimus is an mTOR inhibitor that suppresses T-cell and B-cell proliferation. Tacrolimus is a calcineurin inhibitor that blocks T-cell activation by preventing IL-2 production. Prednisone is a corticosteroid that broadly suppresses immune cell function. Together, they provide synergistic immunosuppression to prevent allograft rejection.
Approved indications
- Prevention of organ rejection in renal transplant recipients
Common side effects
- Infection
- Nephrotoxicity
- Hyperglycemia
- Hypertension
- Hyperlipidemia
- Bone marrow suppression
- Gastrointestinal disturbances
Key clinical trials
- ECP-DL Cell Infusion for Induction in Living Donor Kidney (LDK) Transplants (PHASE1)
- Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant (PHASE4)
- Expanding Liver Transplant Immunosuppression Minimization Via Everolimus (PHASE2)
- Efficacy of a Quadruple Immunosuppressor Regimen With mTOR Inhibitors in Sensitized Kidney Transplant Patients (PHASE4)
- Impact of Photopheresis in the Prevention of Acute Rejection in Highly Sensitized de Novo Kidney Transplant Recipients (NA)
- Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation (PHASE4)
- De Novo Everolimus Versus Tacrolimus in Combination With Mofetil Mycophenolate and Low Dose Corticosteroids to Reduce Tacrolimus Induced Nephrotoxicity in Liver Transplantation: a Prospective, Multicentric, Randomised Study (PHASE3)
- Treg Adoptive Therapy for Subclinical Inflammation in Kidney Transplantation (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Everolimus+Tacrolimus+Prednisone CI brief — competitive landscape report
- Everolimus+Tacrolimus+Prednisone updates RSS · CI watch RSS
- Fundação Pró Rim portfolio CI